Results: Open repair patients were 2 years younger (71 vs 74 years, P < .001), had larger aneurysms (6.01 ؎ 1.38 cm vs 5.45 ؎ 0.99 cm, P < .001), greater familial predisposition, a higher incidence of current smokers, and a higher incidence of chronic obstructive pulmonary disease than the EVAR group. There were no differences in renal function, hypertension, coronary artery disease, or heart failure between the two groups. Overall operative mortality was 3.1%; operative mortality per group was 3.5% for open and 2.7% for EVAR (P ‫؍‬ .627). Procedure-related outcomes showed significant differences in operative blood loss and length of hospital stay in favor of EVAR, and 95% of the EVAR patients were discharged home vs 83% 
The past decade has brought about a major change in the approach to patients with aortic aneurysms. The ongoing enthusiasm to find less-invasive means of managing all forms of vascular disease has resulted in the evolution of catheter-based techniques that can be applied to every major vascular bed.
Open repair of abdominal aortic aneurysms (AAA) has always been considered among the most major of surgical procedures, and the potential complications, which are decreasing in frequency, are highly morbid. It is not surprising that endovascular aneurysm repair (EVAR) was a welcome addition to the procedural armamentarium of the vascular surgeon. Vascular disease, however, is a lifelong problem and most often associated with significant comorbidities that frequently will determine the outcome of major vascular reconstructions.
Unquestionably, operative management has improved, and the advances in critical care have reduced operative morbidity and mortality. EVAR has reduced the need for intensive care unit stay and blood transfusions, shortened hospital stays, and in some studies, decreased procedurerelated and aneurysm-related mortality. 1, 2 The reduction in operative mortality observed in randomized trials has not been observed in all studies, however, and has not yet translated into better survival during longer term follow-up.
Many centers became involved with EVAR as part of registration trials for new devices. Such trials had specific guidelines for graft implantations. Once devices received United States Food and Drug Administration approval, guidelines for use continued but physician judgment became more prominent in patient selection.
During the last 10 years, the Jobst Vascular Center has offered endovascular and open repair to patients undergoing elective treatment of their infrarenal AAA. This study reviewed the procedure-related morbidity and mortality of open and EVAR and investigated the effect of these procedures on mid-term and long-term survival. Computed tomography (CT) scans and arteriography were obtained in nearly every case of EVAR early in the experience and evolved to CT scans alone as the sole imaging method during the latter part of the study. CT scans were the predominant imaging method for patients having open repair.
PATIENTS AND METHODS

All
Main outcome measures were operative death (defined as death Յ30 days of the procedure or during the same hospitalization, whichever was longer), blood loss, length of hospital stay, status at discharge, and long-term mortality.
The EVAR group was monitored with physical examination and serial CT scans and plain abdominal radiographs at 1, 6, 12, 18, and 24 months, and yearly thereafter.
Patients in the open repair group were monitored at 1, 6, and 12 months with physical examination and generally every 6 to 12 months thereafter. Postoperative imaging was not routinely performed in patients having open repair. Follow-up data were retrieved from the hospital database, the inpatient and outpatient data systems, and the Social Security Registry.
Statistical analysis. Cumulative event rates were determined with Kaplan-Meier survival analysis, and the probability difference between patients undergoing open and EVAR repair was compared using log-rank analysis.
Patient characteristics between open and EVAR groups were compared using 2 or the Fisher exact test for categoric variables and the Student t test for continuous variables; data that were not normally distributed were analyzed using the Mann-Whitney rank sum test. Data are expressed as the mean value Ϯ SD or as frequencies and percentages. A value of P Ͻ .05 was considered statistically significant. Statistical analyses were performed with the use of commercially available software (NCSS, Kaysville, Utah).
RESULTS
Patient characteristics.
Of the 677 patients who underwent elective infrarenal AAA repair, 417 had conventional open repair and 260 had EVAR. Demographic characteristics and comorbidities of the patients are listed in Table I . Compared with the EVAR group, the patients undergoing open repair were 3 years younger (71 vs 74 years, P Ͻ .001) but had larger aneurysms (6.01 Ϯ 1.38 vs 5.45 Ϯ 0.99, P Ͻ .001), greater familial predisposition (P ϭ .039), and more current smokers (P ϭ .011), which likely contributed to more chronic obstructive pulmonary disease (P ϭ .001).
There were no differences in renal function, hypertension, coronary artery disease, or heart failure between the two groups. The open repair group had 324 men (77.7%) and 93 women (22.3%), and the EVAR group had 207 men (79.6%) and 53 women (20.4%), with no differences in gender distribution. Most patients in both groups were in their eighth decade of life. The mean follow-up time was 1078 Ϯ 52 days for the EVAR group and 1665 Ϯ 41 days for the open repair group (P Ͻ .0001).
Gender analysis. A significant gender difference was found in our patient population with regards to age, with women being 4 years older than men (75 vs 71 years, P Ͻ .004) at the time of intervention. This observation persisted for each treatment group. Women also presented with smaller aneurysms (5.5 cm) than men (6.2 cm, P Ͻ .001).
Aneurysm specifics. Aneurysms were larger in the open repair group (mean, 6.01 Ϯ 1.38 cm) compared with the EVAR group (mean, 5.45 Ϯ 0.99 cm, P Ͻ .001). In the open repair group, both tube grafts and bifurcated grafts were used as dictated by aneurysm morphology and surgeon preference. The devices used in the EVAR group were 183 Anurex, 24 Vangard, 15 Zenith, 12 Excluder, 9 AnCure, 7 Lifepath, 6 Baxter, and 4 Talent.
Operative mortality. Overall operative mortality was 3.1%. Operative mortality was 3.5% for the open repair group and 2.7% for the EVAR group (P ϭ .627; Table II) . A perceptible difference was found in operative mortality by age (Table II) . Only three patients Ͻ70 years died from elective AAA repair (1.3%), and all had open repair. For patients Ն80 years of age, operative mortality increased to 9.5% in the open repair group and 6.6% in the EVAR group (P ϭ NS). Other operative outcomes. Statistically significant differences, all in favor of EVAR (Table III) , were seen in the amount of estimated blood loss (2532 Ϯ 1982 mL vs 536 Ϯ 708 mL, P Ͻ .001), length of stay (9 Ϯ 9.7 days vs 3.4 Ϯ 3.7 days, P Ͻ .001), and patients discharged to home (83% vs 95%, P Ͻ .001).
Mid-term and long-term survival. Operative mortality was similar between the two treatment groups. Longterm mortality at 1, 3, and 5 years for each group is shown in Table IV . Only one aneurysm-related death in the current series occurred after the postoperative period. An overall Kaplan-Meier log-rank survival analysis showed no difference between the two treatment groups (P ϭ .20); however, 2 analysis of the long-term mortality results indicates that there was a mid-term (3-year) survival benefit favoring open repair (P Ͻ .002; Fig 1) . Since many believe the benefit of EVAR may be greater in older patients, we analyzed operative and long-term survival for patients Ն70 years (Fig 2) 1,2,4 Mortality results reported here are surprisingly similar to those reported in the Lifeline registry. EVAR patients were older than those undergoing open repair, women were older than men, and women had smaller aneurysms than men. Freedom from aneurysm-related rupture remained excellent in both groups throughout follow-up. The survival curves in our patients and in those of the Lifeline registry (Fig 3) have a striking similarity. Although there is no difference in procedure-related or long-term mortality, there is a significant separation of mid-term (2.5-year to 3-year) mortality favoring those who have open repair. The reasons for this observation are speculative, but may include more intense patient evaluation and better control of cardiovascular risk factors over the mid-term in open repair patients.
Operative mortality is usually associated with age and is no different in this series. We were gratified to find that no patient Ͻ60 years of age died as a result of elective operation for their AAA, and only three patients Ͻ70 years old died. Although a much higher procedure-related mortality occurred in patients Ն80 years (9.5% open, 6.5% EVAR), the differences were not significant. Sicard et al 5 reported similar findings, with postoperative mortality no different for open and EVAR groups. They also noted that the subgroup of patients Ն80 years had an overall higher mortality, but less so in patients undergoing EVAR.
Reduced procedure-related length of stay in the intensive care unit and in the hospital is a consistent observation of EVAR-treated patients compared with open repair. 1, 2, 6 This advantage is muted by the increasing number of repeat procedures over time in EVAR patients, which are associated with requisite hospitalization. Carpenter et al 6 reported that the procedure-related length-of-stay advantage to EVAR was lost during the first year of follow-up owing to the readmissions required for subsequent aneurysmrelated procedures. When total hospital days were compared at 12 months, no difference existed between EVAR and open repair patients. As follow-up continues over the long term, the additional procedures required may actually place EVAR patients at a disadvantage in a length-of-stay analysis.
Patients undergoing EVAR have a significant reduction in blood loss and the need for transfusions. Translating the short-term benefit into a long-term advantage relates to the risk of blood-borne diseases. This risk in the United States is miniscule compared with other comorbidities facing patients and is unlikely to translate into meaningful clinical observations.
CONCLUSION
Open repair and EVAR can both be performed safely in patients treated for elective infrarenal AAA. Owing to the low operative mortality of open repair in patients Ͻ70 years old, open repair should be liberally applied in younger patients with AAA. EVAR clearly has perioperative advantages of reduced blood loss, decreased length of hospital stay, and an increased number of patients discharged to home. Early and late survival curves are similar; however, the long-term follow-up in EVAR patients is limited. The midterm survival advantage in open repair patients noted here and in other reports deserves greater study. If specific factors can be identified that correlate with this midterm survival advantage, perhaps improved survival over the long term can be enjoyed by both treatment groups.
We recognize the contributions of Steven Dosick, MD, Steven Gale, MD, Andrew Seiwert, MD, and Ralph Whalen, MD, who were responsible for much of these clinical data, and gratefully acknowledge the editorial and technical assistance of Marilyn Gravett and Victor Cantu. 
AUTHOR CONTRIBUTIONS
Conception
